PATH vs PTHS · P/E 19, rev $1.61B vs rev $7.4M
Uipath Inc (PATH) versus Pelthos Therapeutics Inc. (PTHS) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Pelthos Therapeutics Inc. (PTHS) is a biotechnology company listed on AMEX.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported PTHS revenue for 2025-09-30 was $7.4M. Net income was -$16.2M. PTHS currently screens at market cap $94.7M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. PTHS currently screens at market cap $94.7M.
Not investment advice. Open the PATH and PTHS stock pages for the full models.
Not investment advice.